Cargando…

Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis

Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients often do not receive sacubitril/valsartan because of concerns about hypotension. We exami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyoeun, Oh, Jaewon, Lee, Sanghyup, Ha, Jaehyung, Yoon, Minjae, Chun, Kyeong-hyeon, Lee, Chan Joo, Park, Sungha, Lee, Sang-Hak, Kang, Seok-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358003/ https://www.ncbi.nlm.nih.gov/pubmed/34381126 http://dx.doi.org/10.1038/s41598-021-95787-w

Ejemplares similares

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020)

Comparison of the Association Between Arterial Stiffness Indices and Heart Failure in Patients With High Cardiovascular Risk: A Retrospective Study
por: Lee, Chan Joo, et al.
Publicado: (2021)

The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
por: Chun, Kyeong‐Hyeon, et al.
Publicado: (2020)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

The Association Between On-treatment Ambulatory Central Blood Pressure and Left Ventricular Reverse Remodeling in Heart Failure With Reduced Ejection Fraction
por: Ha, Jaehyung, et al.
Publicado: (2023)

Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study
por: Park, Jin Joo, et al.
Publicado: (2022)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
por: Norberg, Helena, et al.
Publicado: (2019)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
por: Oh, Ji‐Hye, et al.
Publicado: (2022)

Post-transplant absolute lymphocyte count predicts early cytomegalovirus infection after heart transplantation
por: Yoon, Minjae, et al.
Publicado: (2021)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
por: Peppin, Katie L., et al.
Publicado: (2020)

Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
por: Ha, Jaehyung, et al.
Publicado: (2021)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
por: Vilela-Martin, José Fernando
Publicado: (2016)

Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry
por: Oh, Jaewon, et al.
Publicado: (2019)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
por: Ding, Ying, et al.
Publicado: (2023)

Association of muscular fitness with rehospitalization for heart failure with reduced ejection fraction
por: Lee, Chan Joo, et al.
Publicado: (2020)

Statin Therapy in HIGH-Risk Individuals with NORMal Coronary Arteries: The HIGH-NORM Study
por: Chun, Kyeong-Hyeon, et al.
Publicado: (2022)

LncRNA HSPA7 in human atherosclerotic plaques sponges miR-223 and promotes the proinflammatory vascular smooth muscle cell transition
por: Ann, Soo-jin, et al.
Publicado: (2021)

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy
por: Huang, Hsin‐Ti, et al.
Publicado: (2022)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
por: López‐Azor, Juan Carlos, et al.
Publicado: (2019)

Devastating Worsening Renal Function Following the Initiation of Sacubitril/Valsartan: Falling Between Two Stools
por: Sairaku, Akinori, et al.
Publicado: (2023)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s9b2l0npj8lume4bpol8qkhct7